ProCE Banner Activity

Expert Answers to Questions Regarding the Optimal Treatment of CLL

Clinical Thought

In this commentary, experts answer questions about the optimal treatment of chronic lymphocytic leukemia (CLL) asked at a live symposium at ASH 2024. 

Released: January 21, 2025

Expiration: January 20, 2026

Share

Faculty

Danielle M. Brander

Danielle M. Brander, MD

Associate Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Department of Medicine, Duke University
Director, CLL/Lymphoma Research
Duke Cancer Institute
Durham, North Carolina

Brian Hill

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Sameer A. Parikh

Sameer A. Parikh, MBBS

Consultant, Division of Hematology
Chair, CLL Disease Team
Vice Chair, Lymphoid Malignancies Disease Group
Mayo Clinic Comprehensive Cancer Center
Associate Professor of Medicine
Assistant Professor of Oncology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

AstraZeneca

BeiGene

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Danielle M. Brander, MD

Associate Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapy
Department of Medicine, Duke University
Director, CLL/Lymphoma Research
Duke Cancer Institute
Durham, North Carolina

Danielle M. Brander, MD: consultant/advisor: AbbVie, BeiGene, Genentech, Juno/Celgene/Bristol Myers Squibb, Pharmacyclics; researcher (paid to institution): AbbVie, ArQule/Merck, AstraZeneca/Acerta, BeiGene, Catapult, DTRM, Genentech, Juno/Celgene/Bristol Myers Squibb, NeWave, Nurix, Novartis, Pharmacyclics, TG Therapeutics; other financial or material support: AbbVie, Pharmacyclics.

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian Hill, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech.

Sameer A. Parikh, MBBS

Consultant, Division of Hematology
Chair, CLL Disease Team
Vice Chair, Lymphoid Malignancies Disease Group
Mayo Clinic Comprehensive Cancer Center
Associate Professor of Medicine
Assistant Professor of Oncology
Mayo Clinic
Rochester, Minnesota

Sameer A. Parikh, MBBS: researcher (paid to institution): AstraZeneca, Genentech, Janssen, Merck; consultant/advisor (paid to institution): AbbVie, Amgen, AstraZeneca, BeiGene, Genentech, Janssen, Kite Pharma, Merck, MingSight, Novalgen, Pharmacyclics, TG Therapeutics.